Bottom line
XLV vs RSPH: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and RSPH (Invesco S&P 500 Equal Weight Health Care ETF) are quite different portfolios: only about 19% of their top holdings (by weight) are shared.
XLV is cheaper at 0.08% vs 0.4% — a difference of $32 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +4.7% for RSPH.
Updated Nov 19, 2026
XLV vs RSPH side by side
| XLV | RSPH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.4% |
| Annual cost per $10k | $8 | $40 |
| 10-yr cost on $10k (prospectus) | $103 | $505 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | — |
| 1-yr return | +14.5% | +9.3% |
| 5-yr return (annualized) | +8.1% | +4.7% |
| 10-yr return (annualized) | +9.8% | +8.2% |
| Best quarter | +14.5% | +17.5% |
| Worst quarter | −12.7% | −14.3% |
| Net assets (fund) | $40.6B | $766.9M |
| Number of holdings | 65 | 63 |
| Portfolio turnover | 2% | 24% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | RSPH | Difference |
|---|---|---|---|
| 2025 | +14.5% | +9.3% | +5.2% |
| 2024 | +2.5% | −0.8% | +3.3% |
| 2023 | +2.0% | +3.9% | −1.9% |
| 2022 | −2.1% | −9.2% | +7.2% |
| 2021 | +25.9% | +23.0% | +2.9% |
| 2020 | +13.3% | +18.9% | −5.6% |
| 2019 | +20.7% | +25.3% | −4.7% |
| 2018 | +6.3% | −0.3% | +6.6% |
| 2017 | +21.7% | +23.4% | −1.7% |
| 2016 | −2.8% | −4.5% | +1.7% |
Source: Fund prospectus bar charts
Holdings overlap
7 of XLV's top 25 holdings also appear in RSPH's top 25.
| Holding | XLV | RSPH |
|---|---|---|
| AbbVie Inc | 7.74% | 1.73% |
| Amgen Inc | 3.40% | 1.77% |
| Thermo Fisher Scientific Inc | 3.24% | 1.84% |
| Abbott Laboratories | 2.75% | 1.83% |
| Bristol-Myers Squibb Co | 2.05% | 1.82% |
| Regeneron Pharmaceuticals Inc | 1.08% | 1.96% |
| Cencora Inc | 0.96% | 1.71% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
RSPH top 10
- Bio-Techne Corp. — 2.13%
- IQVIA Holdings Inc. — 2.00%
- Baxter International Inc. — 1.99%
- Regeneron Pharmaceuticals, Inc. — 1.96%
- Mettler-Toledo International Inc. — 1.94%
- Charles River Laboratories International, Inc. — 1.93%
- Veeva Systems Inc. — 1.93%
- DaVita Inc. — 1.87%
- Moderna, Inc. — 1.85%
- Thermo Fisher Scientific Inc. — 1.84%
FAQ
What is the difference between XLV and RSPH?
Which is cheaper, XLV or RSPH?
Should I own both XLV and RSPH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.